Clay Siegall is a Seattle-based leading innovator in the field of biotechnology and cancer-related therapies. He currently serves on the board of Seattle Genetics, as well as serving as the firm’s CEO and President. He co-founded the firm in 1998 with the goal of providing scientific innovation centered on assisting cancer patients through meticulous drug development and research practices.
From his education and training at the University of Maryland, Clay Siegall received a B.S degree in Zoology before proceeding to the George Washington University where he earned a Ph.D. in Genetics.
Before the establishment of Seattle Genetics, he had served at the National Cancer Institute as Biotechnology Fellow and Staff Fellow. Dr. Siegall embarked on his career in research at the Bristol-Myers Squibb Pharmaceutical Research Institute, working as a Senior Research Investigator, and later on as a Principal Scientist.
Clay Siegall has over 20 years of cancer research under his belt. Throughout his career, he has had an unwavering commitment to alleviating the pain and suffering experienced by cancer patients and improving their general quality of life. He is guided by a constant need to create and implement innovative research breakthroughs in cancer therapies.
Under the guidance of Dr. Siegall, Seattle Genetics was one of the first companies to develop an antibody drug conjugate (ADC), known as ADCETRIS, in partnership with Takeda Pharmaceutical Company. The drug received FDA approval in 2011 and is currently available to cancer patients in over 65 countries globally. The expanding global impact of ADCETRIS is proof of Clay Siegall’s commitment to fast-tracking cancer therapies in the medical community.
He has also overseen strategic partnerships for its ADCs with more than twenty collaborative programs with firms such as AbbVie, Genentech, GlaxoSmithKline, and Pfizer. Such partnerships ensure the use of its leading ADC technology in both preclinical and clinical drug developments.
Dr. Siegall’s visionary leadership has enabled him to raise more than $1.2 billion in capital for Seattle Genetics. This includes both private and public investors, as well as the firm’s IPO in 2001. This investment influx has contributed to the growth and development of the firm, with its stock value tripling in the stretch of 5 years.
Clay Siegall has over 15 patents and has currently published over 70 research articles. He also serves on the panels of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, and the Washington Roundtable.
In 2013, he received the University of Maryland Alumnus of the Year award for Computer, Math, and Natural Sciences.